Biogen Idec and Elan Announce Re-Initiation of TYSABRI(R) Clinical Trial Dosing in Multiple Sclerosis
RedNova Wed, 29 Mar 2006 4:05 PM PST
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc. (NYSE: ELN) announced today that they have enrolled and dosed the first patients in the TYSABRI(R) (natalizumab) monotherapy safety extension study program in multiple sclerosis (MS).

Cannabis truly helps multiple sclerosis sufferers New Scientist Wed, 29 Mar 2006 11:09 PM PST Long-term use of therapeutic cannabinoids appears to offer real muscular benefits to patients - not just a boost in mood

How Many Americans Have Multiple Sclerosis? No One Knows With Absolute Certainty Medical News Today Wed, 29 Mar 2006 3:08 PM PST No one knows with absolute certainty how many people in the U.S. are diagnosed with MS every year ("incidence") or how many have MS right now ("prevalence"), although the National MS Society estimates that about 400,000 people have the disease. Steps are now being taken by a federal agency and by the National MS Society to rectify this uncertainty, including a proposal to develop a national

Biogen, Elan retest MS drug, see FDA action by June Reuters via Yahoo! News Wed, 29 Mar 2006 5:41 PM PST Biogen Idec and Elan Corp said on Wednesday they have restarted a safety trial of its multiple sclerosis drug Tysabri, which the drugmakers recalled from the market after reports of rare brain infection were linked to the drug.

Higher wages may cut health care Detroit News Thu, 30 Mar 2006 1:17 AM PST CLINTON TOWNSHIP -- There are few things David DeMotigny can do for himself anymore. At 44 years old, multiple sclerosis essentially has left him paralyzed.

Cork GP under investigation in stem-cell therapy allegation Irish Examiner Thu, 30 Mar 2006 1:43 AM PST A GP in Co Cork is reportedly under investigation for allegedly providing controversial stem-cell therapies to multiple sclerosis sufferers.

Vaccine could stop MS in its tracks New Scientist Wed, 29 Mar 2006 11:33 PM PST The immune cells that attack the brain and nerves of people with multiple sclerosis could be turned into a weapon against the disease

Biogen, Elan retest MS drug, see FDA action by June RedNova Wed, 29 Mar 2006 8:29 PM PST CHICAGO (Reuters) - Biogen Idec and Elan Corp said on Wednesday they have restarted a safety trial of its multiple sclerosis drug Tysabri, which the drugmakers recalled from the market after reports of rare brain infection were linked to the drug. A U.S.

Watchdog probes MS stem cell therapy Irish Examiner Wed, 29 Mar 2006 4:27 PM PST By Claire O’Sullivan THE Irish Medicines Board is investigating the provision of stem cell therapy to multiple sclerosis sufferers at a cost of €18,500 for a three-hour session.

Biogen, Elan Re-Launch Tysabri Trial RedNova Wed, 29 Mar 2006 4:07 PM PST Biogen Idec and Elan said Wednesday they are re-launching human trials of multiple sclerosis treatment Tysabri.